Novartis International AG http://www.novartis.com Pivotal study published in JAMA confirms potential of Novartis candidate vaccine Bexsero® to help protect infants against devastating meningococcal serogroup B disease 2012-02-07T22:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2012/1583402.shtml FDA approves Novartis drug Glivec® label recommending extending treatment to three years for certain GIST patients after surgery 2012-02-01T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2012/1581641.shtml Novartis extends commitment to help achieve final elimination of leprosy 2012-01-30T12:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2012/1581023.shtml Novartis delivers strong underlying financial performance in 2011, expects 2012 sales to be in line with 2011 2012-01-25T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2012/1579903.shtml CHMP recommends EU approval to update Novartis drug Glivec® label to include three year treatment for GIST patients after surgery 2012-01-20T15:43:58 CET http://www.novartis.com/newsroom/media-releases/en/2012/1579137.shtml Novartis drug Signifor® recommended by CHMP for EU approval to treat patients with Cushing's disease 2012-01-20T13:40:07 CET http://www.novartis.com/newsroom/media-releases/en/2012/1579088.shtml Sandoz initiates two more Phase III biosimilar trials, reinforcing long-term global leadership commitment 2012-01-19T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2012/1578463.shtml Novartis receives approval for Lucentis® and launches Galvus® in China, two innovative therapies that support public health goals 2012-01-18T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2012/1578311.shtml Novartis to restructure US business to strengthen competitive position in light of loss of Diovan® patent and announces charge for Rasilez®/Tekturna® 2012-01-13T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2012/1577296.shtml Novartis Consumer Health Inc. voluntarily recalls certain over-the-counter products in the US while Novartis Group strengthens quality standards across all manufacturing sites 2012-01-08T17:47:00 CET http://www.novartis.com/newsroom/media-releases/en/2012/1575836.shtml